PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.88%
Revenue growth under 50% of META's 18.55%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
8.48%
Gross profit growth under 50% of META's 23.12%. Michael Burry would be concerned about a severe competitive disadvantage.
14.68%
EBIT growth below 50% of META's 32.13%. Michael Burry would suspect deeper competitive or cost structure issues.
14.68%
Operating income growth under 50% of META's 32.13%. Michael Burry would be concerned about deeper cost or sales issues.
-0.92%
Negative net income growth while META stands at 33.04%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.32%
Share change of 0.32% while META is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
0.48%
Diluted share change of 0.48% while META is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-0.66%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-9.08%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
3997.74%
10Y CAGR of 3997.74% while META is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
206.93%
5Y CAGR of 206.93% while META is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
79.77%
3Y CAGR of 79.77% while META is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
No Data
No Data available this quarter, please select a different quarter.
300.53%
OCF/share CAGR of 300.53% while META is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
79.05%
3Y OCF/share CAGR of 79.05% while META is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
4274.09%
10Y net income/share CAGR of 4274.09% while META is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
143.89%
Net income/share CAGR of 143.89% while META is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
584.69%
3Y net income/share CAGR of 584.69% while META is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
No Data
No Data available this quarter, please select a different quarter.
217.23%
Equity/share CAGR of 217.23% while META is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
99.40%
Equity/share CAGR of 99.40% while META is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.31%
AR growth of 5.31% while META is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
No Data
No Data available this quarter, please select a different quarter.
5.05%
Asset growth of 5.05% while META is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
5.70%
BV/share growth of 5.70% while META is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
No Data
No Data available this quarter, please select a different quarter.
-7.34%
Our R&D shrinks while META invests at 14.81%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
36.81%
SG&A growth well above META's 8.67%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.